PD-1/PD-L1与胶质母细胞瘤关系的研究进展

胶质母细胞瘤（glioblastoma,GBM）是目前已知最具侵袭性和致命性的原发脑肿瘤，虽然进行了广泛的研究，预后依旧很差，中位生存期仅为15个月左右。而随着人们对血脑屏障的进一步认知以及中枢神经系统与颈深部淋巴系统密切联系的发现，使得GBM患者可能在免疫治疗这种新颖治疗方式中获得受益。PD-1/PD-L1为免疫调节轴上最主要的靶点，针对PD-1/PD-L1的治疗模式在多种类型肿瘤中取得了突破性进展，但在GBM方面仍处于初始阶段。本文就PD-1/PD-L1检查点与GBM的密切关系进行系统描述，并整理、总结近年来应用于GBM的PD-1/PD-L1免疫抑制剂治疗的临床进展，以期为临床治疗提供参考。

Research progress in the relationship between PD-1/PD-L1 and glioblastoma

Glioblastoma (GBM) is the most aggressive and fatal primary brain tumor known.Despite extensive studies,the prognosis remains poor,with a median survival of only about 15 months.With the further recognition of the blood-brain barrier and the discovery of the close connection between the central nervous system and the deep cervical lymphatic system,GBM patients may benefit from the novel treatment mode of immunotherapy.PD-1/PD-L1 is the main target on the immune regulation axis,and the treatment mode for PD-1/PD-L1 has made breakthrough progress in various types of tumors,but it is still at the initial stage in research of GBM.This artical systematically describes the close relationship between PD-1/PD-L1 checkpoint and GBM,and summarizes the clinical progress of immunotherapy of PD-1/PD-L1 applied to GBM in recent years,so as to provide reference for clinical treatment.